



1fw 1614

ATTORNEY DOCKET NO. 19044.0057U2
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)
Subramaniam Ananthan) Art Unit: 1614
Application No. 10/593,748) Examiner: Unassigned
Filing Date: September 22, 2006) Confirmation No. 3021
For: NONPEPTIDE INHIBITORS OF)
MATRIX METALLOPROTEINASES)

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

NEEDLE & ROSENBERG, P.C.
Customer Number 23859

May 23, 2007

Sir:

Pursuant to the requirements of 37 C.F.R. § 1.56, submitted herewith on the accompanying Information Disclosure Statement List is a listing of documents known to Applicants and/or their attorneys. In accordance with 37 C.F.R. § 1.98(a)(2), copies of any cited U.S. patent or U.S. patent application publication documents are not enclosed. Copies of any cited foreign patent document and/or any non-patent publication are enclosed.

This Information Disclosure Statement is believed to be filed in a timely manner pursuant to 37 C.F.R. § 1.97(b)(3), in that a first Office Action on the merits of the present patent application has not yet been mailed to Applicants.


Consideration of the cited documents and making the same of record in the prosecution of the above-referenced application are respectfully requested.

ATTORNEY DOCKET NO. 19044.0057U2
Application No. 10/593,748

No fee is believed due; however, the Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 14-0629.

Respectfully submitted,

NEEDLE & ROSENBERG, P.C.




Christopher L. Curfman, JD, PhD
Registration No. 52,787

NEEDLE & ROSENBERG, P.C.
Customer Number 23859
(678) 420-9300
(678) 420-9301 (fax)

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8

I hereby certify that this correspondence, including any items indicated as attached or included, is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below.



Christopher L. Curfman, JD, PhD

May 23, 2007
Date



INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

| Complete if Known | |
|----------------------|----------------------|
| Application Number | 10/593,748 |
| Filing Date | September 22, 2006 |
| First Named Inventor | Subramaniam Ananthan |
| Group Art Unit | 1614 |
| Examiner Name | Unassigned |

U.S. PATENT DOCUMENTS

| Examiner's Initials | Cite No. | Document No. | Date | Name | Class | Subclass | Filing Date (if appropriate) |
|---------------------|----------|--------------|------------------|---------------|-------|----------|------------------------------|
| /G.S./ | A1 | 5,977,408 | November 2, 1999 | Levin et al. | 562 | 622 | |
| /G.S./ | A2 | 5,753,653 | May 19, 1998 | Bender et al. | 514 | 227.5 | |

FOREIGN PATENT DOCUMENTS

| Examiner's Initials | Cite No. | Foreign Patent Document Country Code-Number-Kind Code | Date | Name | Translation Yes No |
|---------------------|----------|---|-------------------|--------------------------------------|--------------------|
| /G.S./ | A3 | WO 97/44315 | November 27, 1997 | Warner-Lambert | |
| | A4 | WO 98/47494 | October 29, 1998 | British Biotech Pharmaceuticals Ltd. | |
| | A5 | WO 98/16506 | October 8, 1997 | American Cyanamid Company | |
| | A6 | WO 00/063165 | October 26, 2000 | Fujisaw Pharmaceutical | |
| | A7 | WO 00/44711 A | August 3, 2000 | American Cyanamid Company | |
| | A8 | WO 02/055491 | September 1, 2002 | Bristol-Myers Squibb Company | |
| | A9 | EP 818442 | January 14, 1998 | Pfizer Inc. | |
| | A10 | EP 780386 | October 2, 2002 | F. Hoffman-La Roche AG et al. | |

NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials | Cite No. | Non-Patent Citations (include Author, Title, Publisher, Relevant Pages, Date and Place of Publication) |
|---------------------|----------|---|
| /G.S./ | A11 | Apfel et al., "Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents," <i>J. Med. Chem.</i> , 43:2324-2331 (2000) |
| | A12 | Armarego et al., "Quinazolines. Part XIII. Synthesis and stereochemistry of trans- and cis-decahydroquinazolines," <i>J. Chem. Soc. (C)</i> , 1635-1641 (1969) |
| | A13 | Auerbach et al., "Assays for angiogenesis: A review," <i>Pharm. Ther.</i> , 51:1-11 (1991) |
| | A14 | Bailey et al., "Reduction of cyclic anhydrides with NaBH ₄ , versatile lactone synthesis," <i>J. Org. Chem.</i> , 35:3574-3576 (1970) |
| | A15 | Beckett et al., "Recent advances in matrix metalloproteinase inhibitor research," <i>Drug Disc. Today</i> , 1:16-26 (1996) |
| | A16 | Bernath et al., "Preparation and conformational study of partially saturated 3,1-benzoxazines,3,1-benzoxazin-2-ones and 3,1-benzoxazine-2-thiones," <i>Tetrahedron</i> , 41:1353-1365 (1985) |
| | A17 | Birkedal-Hansen et al., "Matrix metalloproteinase: A review," <i>Crit. Rev. Oral. Biol. Med.</i> , 4:197-250 (1993) |
| | A18 | Bode et al., "The x-ray crystal structure of the catalytic domain of human neutrophil collagenase," <i>EMBO J.</i> , 13:1263-1269 (1994) |
| | A19 | Brown, "MMP inhibitors in the treatment of cancer," <i>Med. Oncology</i> , 14:1-10 (1997) |
| | A20 | Brown, "Clinical studies with MMP inhibitors," <i>APMIS</i> , 107:174-180 (1999) |
| | A21 | Brown, "Ongoing trials with matrix metalloproteinase inhibitors," <i>Expert Opin. Invest. Drugs</i> , 9:2167-2177 (2000) |
| | A22 | Burns et al., "Nanomolar inhibitors for two distinct biological target families for a single synthetic sequence: A next step in combinatorial library design?" <i>Angew. Chem. Int. Ed.</i> , 37:2848-2850 (1998) |

Examiner Signature:

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE
 STATEMENT LIST**

(Use as many sheets as necessary)

| Complete if Known | |
|----------------------|----------------------|
| Application Number | 10/593,748 |
| Filing Date | September 22, 2006 |
| First Named Inventor | Subramaniam Ananthan |
| Group Art Unit | 1614 |
| Examiner Name | Unassigned |

NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials | Cite No. | Non-Patent Citations (include Author, Title, Publisher, Relevant Pages, Date and Place of Publication) |
|---------------------|----------|---|
| /G.S./ | A23 | Caldwell <i>et al.</i> , "Phosphinic acid inhibitors of matrix metalloproteinases," <i>Bioorg. Med. Chem. Lett.</i> , 6:323-328 (1996) |
| | A24 | Cheng <i>et al.</i> , "Design and synthesis of piperazine-based MMP inhibitors," <i>J. Med. Chem.</i> , 43:369-380 (2000) |
| | A25 | Clark <i>et al.</i> , "Computational methods for the prediction of drug-likeness," <i>Drug Discov. Today</i> , 5:49-58 (2000) |
| | A26 | Cockett <i>et al.</i> , "MMPs and metastatic cancer," <i>Biochem. Soc. Symp.</i> , 63:295-313 (1998) |
| | A27 | Curren <i>et al.</i> , "MMPs- their role in tumor invasion and metastasis," <i>Eur. J. Cancer</i> , 36:1621-1630 (2000) |
| | A28 | Davidson <i>et al.</i> , "The Inhibition of Matrix Metalloproteinase Enzymes," <i>Chem. Ind.</i> , 258-261 (1997) |
| | A29 | De <i>et al.</i> , "The next generation of MMP inhibitors: Design and synthesis," <i>Ann NY Acad Sci</i> 878:40-60 (1999) |
| | A30 | Eddershaw <i>et al.</i> , "ADME/PK - app to drug discovery," <i>Drug Disc. Today</i> , 5:409-414 (2000) |
| | A31 | Finzel <i>et al.</i> , "Structural characterizations of nonpeptidic thiadiazole inhibitors of matrix metalloproteinases reveal the basis for stromelysin selectivity," <i>Protein Sci.</i> , 7:2118-2126 (1998) |
| | A32 | Freskos <i>et al.</i> , "Discovery of a novel series of selective MMP inhibitors: Identification of the γ -sulfone-thiols," <i>Bioorg. Med. Chem. Lett.</i> , 9:943-948 (1999) |
| | A33 | Galazka <i>et al.</i> , "Spontaneous propeptide processing of mini-stromelysin-1 mutants blocked my APMA," <i>Biochem.</i> , 38:1316-1322 (1999) |
| | A34 | Gatto <i>et al.</i> , "BAY 12-9566, a novel inhibitor of MMPs with angiogenic activity," <i>Clin. Cancer Res.</i> , 5:3603-3607 (1999) |
| | A35 | Gavuzzo <i>et al.</i> , "Two crystal structures of human collagenase with primed and unprimed-side inhibitor," <i>J. Med. Chem.</i> , 43:3377-3385 (2000) |
| | A36 | Getman <i>et al.</i> , "Discovery of a novel class of potent HIV-1 protease inhibitors," <i>J. Med. Chem.</i> 36:288-291 (1993) |
| | A37 | Goodly <i>et al.</i> , "In vivo modulation of human tumor cell growth by normal human extracellular matrix," <i>Tumor Biology</i> , 15:326-336 (1994) |
| | A38 | Gopurala <i>et al.</i> , "A novel synthetic peptide inhibits tumor invasion and angiogenesis in human cell-biomatrix models," <i>Proc. Am. Assoc. Cancer. Res.</i> , 39:44, Abstract #301 (1998) |
| | A39 | Gowravaram <i>et al.</i> , "Inhibition of MMPs by hydroxamates containing heteroatom-based modifications of the P1 group," <i>J. Med. Chem.</i> , 38:2570-2581 (1995) |
| | A40 | Harmat <i>et. al.</i> , "1,2-disubstituted cyclohexane derived tripeptide aldehydes as novel selective thrombin inhibitors," <i>Bioorg. Med. Chem. Lett.</i> , 8:1249-1254 (1998) |
| | A41 | Heath <i>et al.</i> , "Clinical potential of MMP inhibitors in cancer therapy," <i>Drugs</i> , 59:1043-1055 (2000) |
| | A42 | Hidalgo <i>et al.</i> , "Biotech company shares dive after drug failure," <i>BJM</i> , 321:1039 (2000) |
| | A43 | Hidalgo <i>et al.</i> , "Development of MMP inhibitors in cancer therapy," <i>JNCI</i> , 93:178-193 (2001) |
| | A44 | Ikeda <i>et al.</i> , "Inhibition of gelatinolytic activity in tumor tissues by MMP inhibitors-Application of film in situ zymography," <i>Clin. Cancer. Res.</i> , 6:3290-3296 (2000) |
| | A45 | Keiner <i>et al.</i> , "MMP and metastasis," <i>Can. Chemo. Pharm.</i> , 43:42-51 (1999) |
| | A46 | Kennewell <i>et al.</i> , "Synthesis of γ -aminobutyric acid analogues of restricted conformation-2-(aminomethyl)cycloalkanecarboxylic acids," <i>J. Chem. Soc. Perkin. Trans. I</i> , 2563-2570 (1982) |
| | A47 | Kiyama <i>et al.</i> , "Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors," <i>J. Med. Chem.</i> , 42:1723-1738 (1999) |

Examiner Signature:

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE
 STATEMENT LIST**

(Use as many sheets as necessary)

| Complete if Known | |
|----------------------|----------------------|
| Application Number | 10/593,748 |
| Filing Date | September 22, 2006 |
| First Named Inventor | Subramaniam Ananthan |
| Group Art Unit | 1614 |
| Examiner Name | Unassigned |

NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials | Cite No. | Non-Patent Citations (include Author, Title, Publisher, Relevant Pages, Date and Place of Publication) |
|---------------------|----------|--|
| G.S./ | A48 | Kleinfeld <i>et al.</i> , "X-ray absorption studies of human MMP-2 bound to a selective mechanismbased inhibitor," <i>JBC</i> , 276:17125-17131 (2001) |
| | A49 | Kleinman <i>et al.</i> , Basement membrane complexes with biological activity," <i>Biochem.</i> , 25:312-318 (1986) |
| | A50 | Krumme <i>et al.</i> , "Hydroxamate derivates of substrate-analogous peptides containing aminomalonic acid are potent inhibitors of matrix metalloproteinases," <i>FEBS Lett.</i> , 436:209-212 (1998) |
| | A51 | Kruger <i>et al.</i> , "Hydroxamate-type MMP inhibitor Batimastat promotes liver metastasis," <i>Cancer Res.</i> , 61:1272-1275 (2001) |
| | A52 | Kurokawa <i>et al.</i> , "Synthesis of Octahydro-11-oxodibenz[b,e]oxepins and -Octahydro-11-oxodibenz[b,e]thiepins," <i>Chem. Pharm. Bull.</i> , 31:4312-4318 (1983) |
| | A53 | Levin <i>et al.</i> , "The synthesis and biological activity of a novel series of diazepine MMP inhibitors," <i>Bioorg. Med. Chem. Lett.</i> , 8:2657-2662 (1998) |
| | A54 | Levin <i>et al.</i> , "Heteroaryl and cycloalkyl sulfonamide hydroxamic acid inhibitors of matrix metalloproteinases," <i>Med. Chem. Lett.</i> , 11:239-242 (2001) |
| | A55 | Levy <i>et al.</i> , "MMP inhibitors: A structure-activity study," <i>J. Med. Chem.</i> , 41:199-223 (1998) |
| | A56 | Lovejoy <i>et al.</i> , "Crystal structure of MMP-1 and -13 reveal the structural basis for selectivity of collagenase complexed with an inhibitor," <i>Science</i> , 263:375-377 (1994) |
| | A57 | MacDougall <i>et al.</i> , "MMP: multifunctional contributors in tumor progression," <i>Cancer Metastasis Rev.</i> , 14:351-362 (1995) |
| | A58 | MacPherson <i>et al.</i> , "Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits," <i>J. Med. Chem.</i> , 40:2525-2532 (1997) |
| | A59 | Maki <i>et al.</i> , "Augmented anti-metastasis efficacy of a selective matrix metalloproteinase inhibitor, MMI-66, in combination with CPT-11," <i>Clin. Exp. Metastasis</i> , 19:519-526 (2002) |
| | A60 | Matter <i>et al.</i> , "Quantitative structure – activity relationship of human neutrophil collagenase (MMP-8) inhibitors using comparative molecular field analysis and X-ray structure analysis," <i>J. Med. Chem.</i> , 42:1908-1920 (1999) |
| | A61 | Matter <i>et al.</i> , "Affinity and selectivity of MMP inhibitors. A chemometric study," <i>J. Med. Chem.</i> , 42:4506-4523 (1999) |
| | A62 | McCawley <i>et al.</i> , "MMP: multifunctional contributors in tumor progression," <i>Mol. Med. Today</i> , 64:149-156 (2000) |
| | A63 | Michaelides <i>et al.</i> , "Recent advances in MMP inhibitors in cancer therapy," <i>Curr. Pharma. Design</i> , 5:787-819 (1999) |
| | A64 | Morgunova <i>et al.</i> , "Structure of human pro-matrix metalloproteinase-2: Activation mechanism revealed," <i>Science</i> , 284:1667-1670 (1999) |
| | A65 | Moriconi and Mazzocchi, "Synthesis of cis- and trans-7-azabicyclo[4.2.0]octanes," <i>J. Org. Chem.</i> , 31:1372-1379 (1996) |
| | A66 | Newman <i>et al.</i> , "The conversion of phenols to thiophenols via dialkythiocarbamates," <i>J. Org. Chem.</i> , 31:3980-3984 (1960) |
| | A67 | Ngu <i>et al.</i> , "A new efficient solid phase synthesis of hydroxamic acids," <i>J. Org. Chem.</i> , 62:7088-7089 (1997) |
| | A68 | Node <i>et al.</i> , "Hard acid and soft nucleophile systems-5. ring-opening reaction of lactones to ω -alkylthio or ω -arylthio carboxylic acids with aluminum halide and thiol.," <i>J. Org. Chem.</i> , 46:5163-5166 (1981) |

Examiner Signature:

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE
 STATEMENT LIST**

(Use as many sheets as necessary)

| Complete if Known | |
|----------------------|----------------------|
| Application Number | 10/593,748 |
| Filing Date | September 22, 2006 |
| First Named Inventor | Subramaniam Ananthan |
| Group Art Unit | 1614 |
| Examiner Name | Unassigned |

NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials | Cite No. | Non-Patent Citations (include Author, Title, Publisher, Relevant Pages, Date and Place of Publication) |
|---------------------|----------|--|
| /G.S./ | A69 | O'Brien <i>et al.</i> , "Structure-activity relationship and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfona MMP inhibitors," <i>J. Med. Chem.</i> , 43:156-166 (2000) |
| | A70 | Ohta <i>et al.</i> , "Effect of combination therapy with matrix metalloproteinase inhibitor MMI-166 and mitomycin C on the growth and liver metastasis of human colon cancer," <i>Japanese J. Cancer. Res.</i> , 92:688-695 (2001) |
| | A71 | Pavlovsky <i>et al.</i> , "X-ray structure of human stromelysin catalytic domain complexed with nonpeptide inhibitors: Implications for inhibitor selectivity," <i>Protein Sci.</i> , 8:1455-1462 (1999) |
| | A72 | Ratnikov <i>et al.</i> , "Determination of MMP activity using biotinylated gelatin," <i>Anal. Biochem.</i> , 286:149-155 (2000) |
| | A73 | Reiter <i>et al.</i> , "Inhibition of MMP-1 and MMP-13 with phosphinic acids that exploit binding in the S ₂ pocket," <i>Bioorg. Med. Chem. Lett.</i> , 9:127-132 (1999) |
| | A74 | Rich, In <i>Comprehensive Medicinal Chemistry</i> ; Hansch, C.; Sammes, P.; Taylor, J.B., Eds.; Pergamon Press: New York, 2:391-441 (1990) |
| | A75 | Russo, "MMP may provide clues in multiple aliments," <i>Scientist</i> , July 5, 1999 |
| | A76 | Santos <i>et al.</i> , "Rodent pharmacokinetic and anti-tumor efficacy studies with a series of synthetic inhibitors of matrix metalloproteinases," <i>Clin. Exp. Metastasis.</i> , 15:499-508 (1997) |
| | A77 | Seymour, "Novel anticancer agents in development: Exciting prospects and new challenges," <i>Cancer Treat. Rev.</i> , 25:301-312 (1999) |
| | A78 | Shalinski <i>et al.</i> , "Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials," <i>Ann. NY Acad. Sci.</i> , 878:236-270 (1999) |
| | A79 | Siegel <i>et al.</i> , "In vitro inhibition of human sarcoma cells' invasive ability of BABIM-a novel human extracellular matrix," <i>Tumor Biology</i> , 15:326-336 (1994) |
| | A80 | Siegel <i>et al.</i> , "Development of a human reconstituted biomatrix for quantitation of the invasiveness," <i>Cancer Lett.</i> , 69:123-132 (1993) |
| | A81 | Singh <i>et al.</i> , "Relationship between structure and bioavailability in a series of hydroxamate based MMI," <i>Bioorg. Med. Chem. Lett.</i> , 5:337-342 (1995) |
| | A82 | Skiles <i>et al.</i> , "MMP inhibitors for treatment of cancer," <i>Ann. Rep. Med. Chem.</i> , 35:167-176 (2000) |
| | A83 | Skotnicki <i>et al.</i> , "Design and synthetic considerations of MMI," <i>Ann. NY Acad. Sci.</i> , 878:61-72 (1999) |
| | A84 | SBIR Grant#R43CA71285-01 2/27/1997 |
| | A85 | Spurlino, "Structural implications in the design of matrix-metalloproteinase inhibitors." In <i>Structure-Based Drug Design</i> , Veerapandian, Ed., Marcel Dekker, Inc., N.Y., 171-189 (1997) |
| | A86 | Stams <i>et al.</i> , "Structure of human neutrophil collagenase reveals large S1' specificity pocket," <i>Nature: Struct. Biol.</i> , 1:119-123 (1994) |
| | A87 | Stetler-Stevenson <i>et al.</i> , "Type IV collagenases in tumor invasion and metastasis," <i>Cancer Metastasis Rev.</i> , 9:289-303 (1990) |
| | A88 | Sticht <i>et al.</i> , "Solution structure of the glycosylated second type 2 module of fibronectin," <i>J. Mol. Biol.</i> , 276:177-187 (1998) |
| | A89 | Stockman <i>et al.</i> , "Solution structure of SL complexed to thiadiazole inhibitors," <i>Protein Sci.</i> , 7:2281-2286 & 2281-2286 (1998) |
| | A90 | Summers <i>et al.</i> , "Matrix metalloproteinase inhibitors and cancer," <i>Ann. Rep. Med. Chem.</i> , 33:131-140 (1998) |

Examiner Signature:

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE
 STATEMENT LIST**

(Use as many sheets as necessary)

| Complete if Known | |
|----------------------|----------------------|
| Application Number | 10/593,748 |
| Filing Date | September 22, 2006 |
| First Named Inventor | Subramaniam Ananthan |
| Group Art Unit | 1614 |
| Examiner Name | Unassigned |

NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials | Cite No. | Non-Patent Citations (include Author, Title, Publisher, Relevant Pages, Date and Place of Publication) |
|---------------------|----------|---|
| G.S./ | A91 | Tamura <i>et al.</i> , "Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives," <i>J. Med. Chem.</i> , 41:640-649 (1998) |
| | A92 | Turbanti <i>et al.</i> , "1,2-Cyclomethylenecarboxylic monoamide hydroxamic derivatives. A novel class on non-aminoacid ACE inhibitors," <i>J. Med. Chem.</i> , 36:699-707 (1993) |
| | A93 | Vu <i>et al.</i> , "MMP-9/gelatinase-B," In "MMPs" Park W. & Mecham R., AP, NY, pg. 115-149 (1998) |
| | A94 | Vukicevik <i>et al.</i> , "Identification of multiple growth factors in Matrigel suggest caution in interpretation of cellular activity," <i>Exp. Cell Res.</i> , 202:1-8 (1992) |
| | A95 | Windsor <i>et al.</i> , "Catalytic domain comparisons of human fibroblast-type collagenase, stromelysin-1 and matrilysin," <i>BBA</i> , 1334:261-272 (1999) |
| | A96 | Williams <i>et al.</i> , "Renin inhibitors containing conformationally restricted P1-P2 dipeptides," <i>J. Med. Chem.</i> , 34:887-900 (1991) |
| | A97 | Woessner, "MMP family," In "MMP" Park W. & Mecham R., AP, NY, pg. 1-14 (1998) |
| | A98 | Woessner, "MMP inhibition: From the Jurassic to the third millennium," <i>Ann. NY Aca. Sci.</i> , 878:388-403 (1999) |
| | A99 | Yu <i>et al.</i> , "MMP-2/gelatinase-A," In "MMPs" Park W. & Mecham R., AP, NY, pg. 85-113 (1998) |
| ↓ | A100 | International Search Report and Written Opinion for PCT/US05/009263 |
| | A101 | International Preliminary Report on Patentability for PCT/US05/009263 |

| | | | |
|--|-----------------|-----------------|------------|
| Examiner Signature: | /Golam Shameem/ | Date Considered | 02/22/2011 |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | |